Premium Upadacitinib Hemihydrate API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Upadacitinib Hemihydrate (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Selective Janus Kinase 1 (JAK1) Inhibitor

Indications: Rheumatoid Arthritis, Psoriatic Arthritis, Atopic Dermatitis, Ulcerative Colitis

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Upadacitinib Hemihydrate distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Upadacitinib Hemihydrate is an advanced, orally bioavailable small-molecule Active Pharmaceutical Ingredient (API). Within the field of immunology and rheumatology, it is classified as a targeted synthetic disease-modifying antirheumatic drug (tsDMARD).

Pharmacologically, this API is distinguished by its highly selective inhibition of the Janus kinase 1 (JAK1) enzyme. While older generations of JAK inhibitors block multiple enzymes in the JAK family (JAK1, JAK2, JAK3, and TYK2) with similar affinity, Upadacitinib is engineered to selectively target JAK1. This enzyme is primarily responsible for transmitting intracellular signals from pro-inflammatory cytokines, including interleukins (such as IL-6) and interferons.

By selectively blocking the ATP-binding site on the JAK1 enzyme, Upadacitinib prevents the phosphorylation and activation of Signal Transducers and Activators of Transcription (STATs). This mechanism effectively halts the transcription of genes responsible for chronic inflammation. Because it exerts minimal inhibitory effects on JAK2 and JAK3, it preserves critical physiological functions related to hematopoiesis and general immune surveillance.

For formulation scientists, integrating this highly selective API allows for the development of potent oral therapeutics capable of slowing the progression of severe autoimmune conditions, including rheumatoid arthritis. In commercial manufacturing, this active ingredient is typically formulated into extended-release (ER) oral solid tablets in 15 mg, 30 mg, and 45 mg dosage strengths.

Sourcing Upadacitinib Hemihydrate in Pakistan: Morgan’s Supply Network

Developing and commercializing advanced targeted therapies requires a highly resilient and traceable raw material pipeline. Procuring specialty immunology APIs for local commercial manufacturing frequently involves navigating extended lead times, stringent customs bottlenecks, and highly complex regulatory compliance. Sourcing UPADACITINIB HEMIHYDRATE Pakistan through Morgan’s localized distribution network mitigates these complex supply chain risks.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary supply vendor secures several operational provisions for your manufacturing facility:

• DRAP Submission Assistance: Morgan coordinates with DRAP-registered API manufacturers to obtain and forward the necessary compliance documentation on your behalf. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether you require a standard batch or are scaling up a high-volume UPADACITINIB HEMIHYDRATE api Pakistan procurement order, we help ensure that your commercial batch schedules and production timelines are met without costly line stoppages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits specific to the hemihydrate form, and a precise particle size distribution (PSD) for predictable behavior during polymer blending and tablet compression processes.

Technical Specifications for QA & R&D

The Upadacitinib Hemihydrate API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hemihydrate
• CAS Number: 2050057-56-0 (Hemihydrate)
• Appearance: White to off-white solid crystalline powder
• Molecular Formula: C17H19F3N6O • 1/2 H2O
• Molecular Weight: 389.38 g/mol (Hemihydrate)
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Detailed solubility parameters across standard organic solvents and aqueous buffers are documented in the technical data sheet to assist your analytical R&D teams with dissolution profiling and extended-release matrix formulation.

Manufacturing and Handling Guidelines for Formulators

Upadacitinib Hemihydrate is a highly potent immunomodulatory compound. Facilities processing this API must enforce strict occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol. Because it is a hemihydrate, precise control of ambient humidity is critical to prevent the active ingredient from absorbing excess moisture or dehydrating, either of which can alter its physical stability and dissolution rate.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks or powered air-purifying respirators (PAPR), chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, milling, and blending stages must be executed within localized exhaust ventilation systems or dedicated negative-pressure containment isolators to prevent the inhalation of airborne particulates and facility cross-contamination.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.